{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:19:59Z","timestamp":1754108399708,"version":"3.28.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Hydroxychloroquine and azathioprine have been routinely used to control and treat primary and secondary Sj\u00f6gren\u2019s syndrome, which potentially triggered some overdoses by these drugs. Toxicity from hydroxychloroquine and azathioprine manifests in the form of cardiac conduction abnormalities, nausea, vomiting, and muscle weakness. Recognizing these unique drug overdoses and management of these toxicities is important. This case report aims to expand our current understanding of these drug overdoses and their management and also underscores the importance of anticipating and identifying fewer common complications, such as hypocalcemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report<\/jats:title><jats:p>A 34-year-old Persian woman with a history of Sj\u00f6gren\u2019s syndrome presented to the emergency department 3.5\u20134 hours after an intentional overdose of hydroxychloroquine and azathioprine and severe hypotension and loss of consciousness. Although the patient was regularly taking other medications, such as fluoxetine, naproxen, and prednisolone, she explicitly clarified that these were not the substances involved in her overdose. Early investigations showed hypokalemia (2.4\u00a0mEq\/L), hypocalcemia (7.5\u00a0mg\/dL), and hypoglycemia (65\u00a0mg\/dL). She was also diagnosed with metabolic acidosis and respiratory alkalosis. The electrocardiogram showed changes in favor of hypokalemia; other lab tests were run on the patient. Supportive treatments were applied, including rapid intravenous fluid dextrose 5%, normal saline, potassium chloride 30\u00a0mEq, and calcium gluconate 100 mg. The patient was managed and monitored overnight in the emergency room and recovered without residual side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Hydroxychloroquine and azathioprine toxicity are considered rare, but it is likely to increase in frequency given the prevalence and increase in autoimmune diseases and the increasing usage of these drugs in treating such diseases. We found hypocalcemia as the presentation to this patient, which needs further investigation into the probable mechanism. Clinicians need to consider the unique effects of hydroxychloroquine and azathioprine poisoning and initiate appropriate emergency interventions to improve the outcomes in similar patients.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13256-024-04390-w","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T01:02:16Z","timestamp":1708995736000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Azathioprine and hydroxychloroquine overdose in Sj\u00f6gren\u2019s syndrome patient with hypocalcemia: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Alireza","family":"Kooshki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omid","family":"Mehrpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samaneh","family":"Nakhaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"4390_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1517\/14740338.2011.566555","volume":"10","author":"C Abarientos","year":"2011","unstructured":"Abarientos C, Sperber K, Shapiro DL, Aronow WS, Chao CP, Ash JY. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. Expert Opin Drug Saf. 2011;10:705\u201314.","journal-title":"Expert Opin Drug Saf"},{"key":"4390_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1177\/0310057X0903700112","volume":"37","author":"N Gunja","year":"2009","unstructured":"Gunja N, Roberts D, McCoubrie D, Lamberth P, Jan A, Simes DC, et al. Survival after massive hydroxychloroquine overdose. Anaesth Intensive Care. 2009;37:130\u20133.","journal-title":"Anaesth Intensive Care"},{"key":"4390_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/ncprheum0292","volume":"2","author":"D Kyburz","year":"2006","unstructured":"Kyburz D, Brentano F, Gay S. Mode of action of hydroxychloroquine in RA\u2014evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol. 2006;2:458\u20139.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"4390_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1146\/annurev.immunol.15.1.821","volume":"15","author":"C Watts","year":"1997","unstructured":"Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol. 1997;15:821.","journal-title":"Annu Rev Immunol"},{"key":"4390_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.berh.2004.02.006","volume":"18","author":"E Tanaka","year":"2004","unstructured":"Tanaka E, Taniguchi A, Urano W, Yamanaka H, Kamatani N. Pharmacogenetics of disease-modifying anti-rheumatic drugs. Best Pract Res Clin Rheumatol. 2004;18:233\u201347.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"4390_CR6","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1084\/jem.20051106","volume":"202","author":"D Accapezzato","year":"2005","unstructured":"Accapezzato D, Visco V, Francavilla V, Molette C, Donato T, Paroli M, et al. Chloroquine enhances human CD8+ T cell responses against soluble antigens . J Exp Med. 2005;202:817\u201328.","journal-title":"J Exp Med"},{"key":"4390_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1080\/00325481.2021.1889820","volume":"133","author":"N Imanova Yaghji","year":"2021","unstructured":"Imanova Yaghji N, Kan EK, Akcan S, Colak RA. Atmaca, Hydroxychloroquine sulfate related hypoglycemia in a non-diabetic COV\u0130D-19 patient: a case report and literature review. Postgrad Med. 2021;133:548\u201351.","journal-title":"Postgrad. Med."},{"key":"4390_CR8","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.ajem.2020.07.030","volume":"38","author":"A Della Porta","year":"2020","unstructured":"Della Porta A, Bornstein K, Coye A, Montrief T, Long B, Parris MA. Acute chloroquine and hydroxychloroquine toxicity: a review for emergency clinicians. Am J Emerg Med. 2020;38:2209\u201317.","journal-title":"Am J Emerg Med"},{"key":"4390_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1172\/JCI200318384","volume":"111","author":"JS Maltzman","year":"2003","unstructured":"Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest. 2003;111:1122\u20134.","journal-title":"J Clin Invest"},{"key":"4390_CR10","first-page":"e3","volume":"58","author":"K Mahmood","year":"2013","unstructured":"Mahmood K, Khan AM, Ramanan AV, Martin K. Intentional overdose of azathioprine in a patient with systemic lupus erythematosus, Scott. Med J. 2013;58:e3\u20134.","journal-title":"Med J"},{"key":"4390_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0002-9343(74)90759-1","volume":"56","author":"DM Carney","year":"1974","unstructured":"Carney DM, Zukoski CF, Ogden DA. Massive azathioprine overdose: case report and review of the literature. Am J Med. 1974;56:133\u20136.","journal-title":"Am J Med"},{"key":"4390_CR12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/practneurol-2018-002161","volume":"20","author":"M McWilliam","year":"2020","unstructured":"McWilliam M, Khan U. Azathioprine and the neurologist. Pract Neurol. 2020;20:69\u201374.","journal-title":"Pract Neurol"},{"key":"4390_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s13181-020-00790-8","volume":"16","author":"PR Chai","year":"2020","unstructured":"Chai PR, Ferro EG, Kirshenbaum JM, Hayes BD, Culbreth SE, Boyer EW, et al. Intentional hydroxychloroquine overdose treated with high-dose diazepam: an increasing concern in the COVID-19 pandemic. J Med Toxicol. 2020;16:314\u201320.","journal-title":"J Med Toxicol"},{"key":"4390_CR14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S0140-6736(51)91643-1","volume":"258","author":"F Page","year":"1951","unstructured":"Page F. Treatment of lupus erythematosus with mepacrine. Lancet. 1951;258:755\u20138.","journal-title":"Lancet"},{"key":"4390_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","volume":"42","author":"I Ben-Zvi","year":"2012","unstructured":"Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012;42:145\u201353.","journal-title":"Clin Rev Allergy Immunol"},{"key":"4390_CR16","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/jac\/dkv018","volume":"70","author":"MAA Al-Bari","year":"2015","unstructured":"Al-Bari MAA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70:1608\u201321.","journal-title":"J Antimicrob Chemother"},{"key":"4390_CR17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1185\/03007995.2014.909393","volume":"30","author":"A Pareek","year":"2014","unstructured":"Pareek A, Chandurkar N, Thomas N, Viswanathan V, Deshpande A, Gupta OP, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin. 2014;30:1257\u201366.","journal-title":"Curr Med Res Opin"},{"key":"4390_CR18","first-page":"53","volume":"14","author":"HT Fung","year":"2007","unstructured":"Fung HT, Lam KK, Wong OF, Lau B, Kam CW. A case of fatal hydroxychloroquine overdose, Hong Kong. J Emerg Med. 2007;14:53\u20137.","journal-title":"J Emerg Med"},{"key":"4390_CR19","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/S0735-1097(17)35729-7","volume":"69","author":"I Ndukwu","year":"2017","unstructured":"Ndukwu I, Ghahramani M. Hydroxychloroquine overdose presenting as acquired QT interval prolongation and torsade de pointes. J Am Coll Cardiol. 2017;69:2340.","journal-title":"J Am Coll Cardiol"},{"key":"4390_CR20","first-page":"3460","volume":"95","author":"FD Goldman","year":"2000","unstructured":"Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ. Hydroxychloroquine inhibit calcium signals in T cells: a new mechanism to explain its immunomodulatory properties, Blood. J Am Soc Hematol. 2000;95:3460\u20136.","journal-title":"J Am Soc Hematol"},{"key":"4390_CR21","unstructured":"A. Goyal, C. Anastasopoulou, M. Ngu and S. Singh, Hypocalcemia, 2017"},{"key":"4390_CR22","unstructured":"W. Jasek, Austria-Codex, Vienna: \u00d6sterreichischer Apothekerverlag 62 2007, pp. 5510\u20135511."},{"key":"4390_CR23","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.toxrep.2019.10.006","volume":"6","author":"JB Radke","year":"2019","unstructured":"Radke JB, Kingery JM, Maakestad J, Krasowski MD. Diagnostic pitfalls and laboratory test interference after hydroxychloroquine intoxication: a case report. Toxicol Rep. 2019;6:1040\u20136.","journal-title":"Toxicol Rep"},{"key":"4390_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/4370648","author":"SM Yousuf","year":"2023","unstructured":"Yousuf SM, Alater AM, Alabdulla M, Osman M. False positive tramadol urine testing in patients taking fexofenadine: a tale of two consecutive cases. Case Rep Psychiatry. 2023. https:\/\/doi.org\/10.1155\/2023\/4370648.","journal-title":"Case Rep Psychiatry"},{"key":"4390_CR25","first-page":"26","volume":"41","author":"S Dakota","year":"2016","unstructured":"Dakota S. Urine drug screening: minimizing false-positives and false-negatives to optimize patient care. US Pharm. 2016;41:26\u201330.","journal-title":"US Pharm"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04390-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-024-04390-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04390-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T23:00:22Z","timestamp":1731452422000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-024-04390-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4390"],"URL":"https:\/\/doi.org\/10.1186\/s13256-024-04390-w","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2024,2,27]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirm that all interventions and screenings were carried out following relevant guidelines and regulations and that informed consent for the participation and publication of this case was obtained from the patient. The patient's identity, privacy, and confidentiality have been maintained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}